Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials

The Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis‐associated Interstitial Lung Disease: A Population‐based Cohort

(2022) Bilal F. Samhouri et al.   ARTHRITIS CARE & RESEARCH

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases

(2022) Francesco Bonella et al.   ADVANCES IN THERAPY

NHLBI Report: Impact of Sex and Gender on Autoimmune Lung Disease, Opportunities for Future Research

(2022) Elizabeth R Volkmann et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment

(2022) Cosimo Bruni et al.   RHEUMATOLOGY

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

(2022) Eric L. Matteson et al.   Arthritis & Rheumatology

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

(2021) Kristin B Highland et al.   Lancet Respiratory Medicine

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

(2021) Ulrike Schmid et al.   BMC Pulmonary Medicine

Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019

(2021) Belén López-Muñiz Ballesteros et al.   Journal of Clinical Medicine

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

(2020) Athol U Wells et al.   Lancet Respiratory Medicine

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

(2020) James R Seibold et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

(2020) Anna-Maria Hoffmann-Vold et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

(2019) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

(2019) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study

(2019) Samantha Alvarez-Madrazo et al.   BMJ Open

Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis

(2018) Ulrike Schmid et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs

(2018) Patrick R. Wood et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study

(2017) Silje Reiseter et al.   RHEUMATOLOGY

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study

(2014) C. A. Kelly et al.   RHEUMATOLOGY

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse effects in women: implications for drug development and regulatory policies

(2011) Ameeta Parekh et al.   Expert Review of Clinical Pharmacology